4D pharma plc, a pharmaceutical company developing Live Biotherapeutics, received expedited acceptance from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to begin a Phase II study of MRx-4DP0004 in COVID-19 patients. Current evidence suggests a reason for the high mortality rate of COVID-19 may be due to the hyper-inflammatory response and cytokine storm syndrome caused by uncontrolled activation of the immune system. Targeted immunomodulation may be beneficial in these pa...